title: Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
abstract: Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have a poor prognosis with conventional chemotherapy. In the present study, we retrospectively analyzed the outcome of patients with BPDCN who underwent allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT). A total of 39 patients (allo-SCT, n = 34; auto-SCT, n = 5) were identified in the European Group for Blood and Marrow Transplantation registry. The 34 allo-SCT patients had a median age of 41 years (range, 10-70) and received transplantations from sibling (n = 11) or unrelated donors (n = 23) between 2003 and 2009. MAC was used in 74% of patients. Nineteen allo-SCT patients (56%) received transplantations in first complete remission. The 3-year cumulative incidence of relapse, disease-free survival, and overall survival was 32%, 33%, and 41%, respectively. By univariate comparison, being in first remission at allo-SCT favorably influenced survival, whereas age, donor source, and chronic GVHD had no significant impact. We conclude that high-dose therapy followed by allo-SCT from related or unrelated donors can provide durable remission even in elderly patients with BPDCN. However, it remains to be shown if graft-versus-malignancy effects can contribute significantly to BPDCN control after allo-SCT.
authors.affiliation: Assistance Publique des Hôpitaux de Paris, Hematology Department, Hôpital Pitié-Salpétrière, 47-83 Bd de l’Hôpital, Paris Cedex, France. damien.roosweil@psl.aphp.fr
authors.forename: Damien
authors.initials: D
authors.lastname: Roos-Weil
authors.forename: Sascha
authors.initials: S
authors.lastname: Dietrich
authors.forename: Ariane
authors.initials: A
authors.lastname: Boumendil
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Polge
authors.forename: Dominique
authors.initials: D
authors.lastname: Bron
authors.forename: Enric
authors.initials: E
authors.lastname: Carreras
authors.forename: Arturo
authors.initials: A
authors.lastname: Iriondo Atienza
authors.forename: William
authors.initials: W
authors.lastname: Arcese
authors.forename: Dietrich W
authors.initials: DW
authors.lastname: Beelen
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Cornelissen
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Milone
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rossi
authors.forename: Fabrice
authors.initials: F
authors.lastname: Jardin
authors.forename: Christina
authors.initials: C
authors.lastname: Peters
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
authors.forename: Anna
authors.initials: A
authors.lastname: Sureda
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Peter
authors.initials: P
authors.lastname: Dreger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000379:methods; D002648:Child; D003713:Dendritic Cells / Q000473:pathology*; D018572:Disease-Free Survival; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000401:mortality; D019337:Hematologic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D012042:Registries / Q000706:statistics & numerical data; D012189:Retrospective Studies; D055815:Young Adult